Anrikefon acetate

Synonyms: HSK21542 acetate
Anrikefon (HSK21542) acetate 是一种外周限制性 κ 阿片受体 (KOR) 激动剂,对人源 KOR 的 IC50 为 0.54 nM、EC50 为 2.41 pM、Ka 为 0.068 nM,且对 μ 和 δ 阿片受体具有高选择性,可通过抑制炎症性、术后和神经性疼痛相关行为产生镇痛作用,并通过减少瘙痒相关行为发挥止痒作用,因此可用于疼痛、瘙痒以及慢性肾脏病相关瘙痒的研究。
产品编号: MS-S50691 纯度: 99.68% CAS No.: 2584931-05-3 分子式: C41H61N7O7 分子量: 763.97
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Anrikefon (HSK21542) acetate 是一种外周限制性 κ 阿片受体 (KOR) 激动剂,对人源 KOR 的 IC50 为 0.54 nM、EC50 为 2.41 pM、Ka 为 0.068 nM,且对 μ 和 δ 阿片受体具有高选择性,可通过抑制炎症性、术后和神经性疼痛相关行为产生镇痛作用,并通过减少瘙痒相关行为发挥止痒作用,因此可用于疼痛、瘙痒以及慢性肾脏病相关瘙痒的研究。

生物实验数据

生物活性 Anrikefon (HSK21542) acetate is a peripherally restricted κ opioid receptor (KOR) agonist with an IC50 of 0.54 nM, an EC50 of 2.41 pM, and a Ka of 0.068 nM for human KOR, and exhibits high selectivity over μ and δ opioid receptors; it produces analgesic effects by inhibiting inflammatory, postoperative, and neuropathic pain-related behaviors and antipruritic effects by reducing itch-related behaviors, and can therefore be used for research on pain, pruritus, and chronic kidney disease-associated pruritus.
体外研究
(In Vitro)

Anrikefon (HSK21542) acetate (0.01-10 nM、0.123-1.23 nM;作用时间 60 min、120 min) 可强效结合分离的 HEK-293 细胞膜上的人源 KOR,其 IC50 为 0.54 nM,Kd 为 0.068 nM,解离半衰期长达 90.6 min。
Anrikefon (HSK21542) acetate (0.001-10 nM;作用 30 min) 可强效抑制表达人 KOR 的 HEK-293 细胞中福司柯林诱导的 cAMP 积累,其 EC50 为 2.41 pM。
Anrikefon (HSK21542) acetate (10 μM) 具有较高的脱靶选择性,仅在 10 μM 的高浓度下与大麻素 CB1 受体有弱结合,且对其他 85 个受试靶点无活性。

体内研究
(In Vivo)

Anrikefon (acetate) (0.01-30 mg/kg; i.v.; single dose) 在醋酸诱导的扭体模型中可产生强效、剂量依赖性的、由 KOR 介导的镇痛作用,给药后 15 分钟的 ED50 为 0.09 mg/kg,给药后 24 小时的 ED50 为 1.48 mg/kg,最小有效剂量 (MED) 为 0.03 mg/kg。
Anrikefon (acetate) (0.1-10 mg/kg; i.v.; single dose) 在足底切口模型中产生剂量依赖性的抗异常痛觉作用,给药后 15 分钟的最低有效剂量 (MED) 为 1 mg/kg,在 3 mg/kg 和 10 mg/kg 剂量下,给药后 24 小时仍能维持疗效。
Anrikefon (acetate) (0.1-3 mg/kg;静脉注射;单次给药) 在 CCI 神经病理性疼痛模型中产生剂量依赖性、长效的抗异常痛觉作用,其 MED 为 0.3 mg/kg,且在 1 mg/kg 和 3 mg/kg 剂量下,给药后 24 小时仍能维持疗效。
Anrikefon (acetate) (0.01-3 mg/kg; i.v.; single dose) 在 compound 48/80 诱导的搔抓模型中可产生强效、剂量依赖性的止痒作用,其 ED50 为 0.09 mg/kg,MED 为 0.03 mg/kg。
Anrikefon (acetate) (3.75-30 mg/kg; i.v.; single dose) 在热板模型中表现出较弱的中枢镇痛作用,其 ED50 为 10.49 mg/kg,MED 为 7.5 mg/kg。
Anrikefon (acetate) (0.4-2 mg/kg; i.v.; single dose) 仅在 2 mg/kg 剂量下对健康大鼠产生镇静作用,0.4 mg/kg 剂量下无显著作用。
Anrikefon (acetate) (0.4-2 mg/kg; i.v.; single dose) 在剂量高达 2 mg/kg 时,不会影响健康小鼠的呼吸频率。
Anrikefon (acetate) (0.5-5 mg/kg per injection; i.v.; twice daily; male: 4 weeks prior to mating through mating until day before necropsy, female: 2 weeks prior to mating through mating until gestation day 7) 在最高达 10 mg/kg/day 的剂量下,对雄性大鼠的生育力或早期胚胎发育无具有毒理学意义的影响,但在所有受试剂量下会延长雌性大鼠的动情周期时长并提高周期紊乱率,其雌性生育力毒性的未观察到有害作用水平 (NOAEL) 低于 1 mg/kg/day。
Anrikefon (acetate) (0.1-2 mg/kg per injection; i.v.; twice daily; gestation day 6 through gestation day 17) 对大鼠的胚胎-胎仔发育而言,NOAEL 为 1 mg/kg/day;仅在 4 mg/kg/day 剂量下观察到胎仔胸椎椎体中心骨化不全的发生率略有升高。
Anrikefon (acetate) (0.3-2 µg/kg/day; i.v.; daily; gestation day 7 through gestation day 19) 对家兔胚胎-胎仔发育的无可见有害作用水平 (NOAEL) 为 2 µg/kg/天,在所有测试剂量下均未观察到对母体或胎仔的不良影响。
Anrikefon (acetate) (0.1-2 mg/kg per injection; i.v.; twice daily; gestation day 6 through postnatal day 21) 对大鼠的产前及产后发育的 NOAEL 为 4 mg/kg/天,在所有受试剂量下均未观察到对母鼠或 F1 代后代的不良影响。

Animal Model: ICR (half male and half female, 8-10 weeks old, 18-22 g)
Dosage: 0.01-30 mg/kg
Administration: i.v.; single dose
Result: Induced a 27.46% inhibition of writhing at 0.03 mg/kg (p=0.023 vs. vehicle). Produced dose-dependent inhibitory effects at 0.1, 1, 3, 10 mg/kg at 15 minutes post-dosing (p<0.001 vs. vehicle), with an ED50 of 0.09 mg/kg (95% CI: 0.06-0.12 mg/kg). Reversed antinociceptive effects of 0.3 and 1 mg/kg completely by nor-binaltorphimine. Induced a 32.75% inhibition of writhing at 0.3 mg/kg at 24 hours post-dosing (p=0.02 vs. vehicle). Produced inhibitory rates of 49.67%, 55.60%, 68.12%, and 75.16% at 1, 3, 10, 30 mg/kg respectively at 24 hours post-dosing (p<0.001 vs. vehicle), with an ED50 of 1.48 mg/kg (95% CI: 0.62-2.45 mg/kg). Achieved a minimum effective dose (MED) of 0.03 mg/kg.
Animal Model: Sprague Dawley (SD) (male, 8-10 weeks old, 160-180 g)
Dosage: 0.1-10 mg/kg
Administration: i.v.; single dose
Result: Induced a 10.5-fold increase in 50% PWT at 1 mg/kg at 15 minutes post-dosing (7.51 g vs. 0.72 g in vehicle group, p=0.001 vs. vehicle). Produced maximum antiallodynic activity at 10 mg/kg at 15 minutes post-dosing, with dose-dependent effects observed across 0.1-10 mg/kg (p<0.001 vs. vehicle). Achieved a MED of 1 mg/kg at 15 minutes post-dosing. Maintained statistically significant increases in 50% PWT at 3 mg/kg (p=0.01 vs. vehicle) and 10 mg/kg (p<0.001 vs. vehicle) at 24 hours post-dosing.
Animal Model: Sprague Dawley (SD) (male, 8-10 weeks old, 160-180 g)
Dosage: 0.1-3 mg/kg
Administration: i.v.; single dose
Result: Induced a 5.15-fold increase in 50% PWT at 0.3 mg/kg at 15 minutes post-dosing (6.62 g vs. 1.29 g in vehicle group). Produced peak 50% PWT at 2 hours post-dosing at 1 and 3 mg/kg, with statistically significant increases maintained through 24 hours post-dosing. Induced a statistically significant increase in AUC at 0.3 mg/kg (p<0.001 vs. vehicle), while 0.1 mg/kg showed no significant effect at any time point. Achieved a MED of 0.3 mg/kg.
Animal Model: ICR (male, 8-10 weeks old, 18-22 g)
Dosage: 0.01-3 mg/kg
Administration: i.v.; single dose
Result: Induced a 34.89% inhibition of scratching at 0.03 mg/kg (p=0.015 vs. vehicle). Produced dose-dependent inhibitory effects at 0.1, 0.3, 1, 3 mg/kg (p<0.001 vs. vehicle), with 1 mg/kg inducing a 99.78% inhibition (peak efficacy). Achieved an ED50 of 0.09 mg/kg (95% CI: 0.04-0.16 mg/kg), and a MED of 0.03 mg/kg.
Animal Model: C57BL/6J (female, 8-10 weeks old, 18-22 g)
Dosage: 3.75-30 mg/kg
Administration: i.v.; single dose
Result: Did not produce significant antinociceptive effects at 3.75 mg/kg (p=0.12 vs. vehicle). Induced a 29.60% MPE at 7.5 mg/kg (p=0.007 vs. vehicle). Achieved an ED50 of 10.49 mg/kg (95% CI: 7.58-15.37 mg/kg), and a MED of 7.5 mg/kg.
Animal Model: Sprague Dawley (SD) (half male and half female, 8-10 weeks old, 160-180 g)
Dosage: 0.4-2 mg/kg
Administration: i.v.; single dose
Result: Did not significantly affect locomotor activity at 0.4 mg/kg (p=0.16 vs. vehicle). Induced a significant sedative effect at 2 mg/kg (p=0.005 vs. vehicle).
Animal Model: ICR (half male and half female, 8-10 weeks old, 18-22 g)
Dosage: 0.4-2 mg/kg
Administration: i.v.; single dose
Result: Did not produce significant changes in respiratory rate at 0.4 or 2 mg/kg at any time point post-dosing (p>0.05 vs. vehicle).
Animal Model: Sprague-Dawley (8-11 weeks, male and female)
Dosage: 1 mg/kg/day; 3 mg/kg/day; 10 mg/kg/day
Administration: i.v.; twice daily at 6-hour intervals; male: 4 weeks prior to mating through mating until day before necropsy, female: 2 weeks prior to mating through mating until gestation day 7
Result: Increased sperm count by 1.19-fold and 1.21-fold vs. vehicle in male rats at 1 and 10 mg/kg/day, within historical control ranges.\nIncreased sperm density by 1.20-fold and 1.23-fold vs. vehicle in male rats at 1 and 10 mg/kg/day, within historical control ranges.\nCaused no changes to sperm motility or morphology in male rats at all doses.\nInduced transient mild body weight decreases in male rats during 4th to 11th day (1, 3 mg/kg/day) or 4th to 15th day (10 mg/kg/day) of dosing.\nIncreased estrous cycle length by 1.10-fold, 1.13-fold, 1.15-fold vs. vehicle in female rats at all doses.\nIncreased estrous cycle disorder rate to 65.4%, 61.5%, 57.7% vs. 23.1% vehicle in female rats at all doses.\nInduced transient mild body weight decreases only on 4th day of dosing in female rats at 1, 3 mg/kg/day.\nIncreased precoital interval in female rats at 10 mg/kg/day.\nDecreased non-gravid uterus weight in female rats at 1 mg/kg/day.\nCaused no treatment-related changes in fertility index, conception index, copulation index, ovarian/uterine contents, or most organ weights.
Animal Model: Sprague-Dawley (pregnant female)
Dosage: 0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day
Administration: i.v.; twice daily at 6-hour intervals; gestation day 6 through gestation day 17
Result: Induced transient, mild decreases in body weight (3.56%-6.33%) from gestation day 8 to gestation day 10 in maternal rats at 1 and 4 mg/kg/day.\nCaused decreased food consumption from gestation day 6 to gestation day 7 in all dose groups.\nCaused no treatment-related changes in maternal reproductive parameters or organ weights.\nIncreased incidence of incomplete ossification of the thoracic vertebral centrum by 3.5% in fetuses at 4 mg/kg/day.\nCaused no changes to fetal weight, sex ratio, or malformation rates at any dose.
Animal Model: New Zealand white (5-6 months, pregnant female)
Dosage: 0.3 µg/kg/day; 1 µg/kg/day; 2 µg/kg/day
Administration: i.v.; daily; gestation day 7 through gestation day 19
Result: Caused no treatment-related changes in maternal body weight, food consumption, reproductive parameters, or organ weights at any dose.\nCaused no changes to fetal weight, malformation rates, or visceral development at any dose.\nDecreased male fetal ratio to 32% vs. 41% in controls in fetuses at 2 µg/kg/day, within historical control ranges (18.3%-60.5%) and deemed non-toxicologically significant.\nResulted in plasma concentration ratios between maternal rabbits and fetuses of 109.0 (1 µg/kg/day) and 163.2 (2 µg/kg/day), confirming small amount crosses placental barrier.
Animal Model: Sprague-Dawley (pregnant female; offspring F1 generation)
Dosage: 0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day
Administration: i.v.; twice daily at 6-hour intervals; gestation day 6 through postnatal day 21
Result: Induced transient, mild decreases in body weight (4.04%-6.56%) from gestation day 8 to gestation day 17 in maternal rats at 1 and 4 mg/kg/day.\nCaused 4.66% decrease in body weight on postnatal day 0 in maternal rats at 1 mg/kg/day.\nIncreased resorptions in maternal rats at 1 mg/kg/day, deemed non-toxicologically significant.\nCaused no treatment-related changes in litter parameters, F1 pup pre-weaning body weight, reflexes, or locomotor activity.\nInduced slight, normal-range body weight increases (3.07%-4.35%) on postnatal day 63-70 in post-weaning F1 females at 1 and 4 mg/kg/day.\nCaused sporadic changes in F1 pup Morris water maze test performance (increased swimming speed in 4 mg/kg/day males on training day 9; increased swimming time in 0.2 and 4 mg/kg/day females on training day 4), deemed non-toxicologically significant.\nAdvanced vaginal opening by 1.54%-1.85% vs. vehicle in F1 females at all doses, deemed non-toxicologically significant.\nCaused no treatment-related changes in F1 pup sexual maturation timing (preputial separation) or reproductive capacity.
性状 固体
颜色 White to off-white

化学信息

分子量 763.97
分子式 C41H61N7O7
CAS No. 2584931-05-3
别名 HSK21542 acetate

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 100 mg/mL (130.90 mM)

DMSO 中的溶解度 : 100 mg/mL (130.90 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM1.3090 mL6.5448 mL13.0895 mL32.7238 mL
5 mM0.2618 mL1.3090 mL2.6179 mL6.5448 mL
10 mM0.1309 mL0.6545 mL1.3090 mL3.2724 mL
15 mM0.0873 mL0.4363 mL0.8726 mL2.1816 mL
20 mM0.0654 mL0.3272 mL0.6545 mL1.6362 mL
25 mM0.0524 mL0.2618 mL0.5236 mL1.3090 mL
30 mM0.0436 mL0.2182 mL0.4363 mL1.0908 mL
40 mM0.0327 mL0.1636 mL0.3272 mL0.8181 mL
50 mM0.0262 mL0.1309 mL0.2618 mL0.6545 mL
60 mM0.0218 mL0.1091 mL0.2182 mL0.5454 mL
80 mM0.0164 mL0.0818 mL0.1636 mL0.4090 mL
100 mM0.0131 mL0.0654 mL0.1309 mL0.3272 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础